This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

James H. Wells, MD; John R. Marshall, MD; Paul P. Carbone, MD

JAMA. 1968;205(13):935-937.

Abstract
Procarbazine hydrochloride, an antineoplastic agent, a teratogen, and a carcinogen, was given to a patient with Hodgkin's disease during the first 5 1/2 weeks of her pregnancy, and a normal infant was delivered. Based on past experience with chemotherapeutic agents given to pregnant women with Hodgkin's disease, the authors present a program of management for the pregnant patient with Hodgkin's disease.

Author Affiliations
From the Laboratory of Chemical Pharmacology (Dr. Wells), the surgery (Dr. Marshall), and medicine (Dr. Carbone) branches, National Cancer Institute, Bethesda, Md. Dr. Wells is now at University Hospital, Ann Arbor, Mich.

Footnotes
Reprint requests to National Cancer Institute, Bethesda. Md 20014 (Dr. Carbone).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

How Is Hodgkin Lymphoma in Pregnancy Best Treated?
Bachanova and Connors
ASH Education Book 2008;2008:33-34.
ABSTRACT | FULL TEXT  

Management of the Pregnant Patient with Hodgkin's Disease
JACOBS et al.
ANN INTERN MED 1981;95:669-675.
ABSTRACT  

Immunosuppressive and Cytotoxic Chemotherapy: Long-Term Complications
SCHEIN and WINOKUR
ANN INTERN MED 1975;82:84-95.
ABSTRACT